Request Trial
Novikov Aleksey / Shutterstock.com
27 August 2026NewsBiotechPaul Calvo

China-origin biotech assets and the hidden question of IP ownership

As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotech
10x and Parse set to end sequencing feud after appeals court defeat
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
Biotech
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.
Biotech
Scientist and Chinese biotech targeted by Beam in secrets suit
29 September 2026   The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.


Editor's picks

WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026

Editor's picks

In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026

More features

‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief
Mewburn Ellis hires first CTO to boost investment in AI and digital innovation
10x and Parse set to end sequencing feud after appeals court defeat
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
Amarin and Hikma call time on six-year skinny label fight
WATCH: Medmix global IP head on building business-focused IP teams
Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise
Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss